MetaVia presents Phase 1 data on dual-receptor obesity/liver drug DA-1726 at EASL

Filed May 27, 2026 · Period ending May 27, 2026 · ~1 min read

Key Changes

• medium

  MetaVia disclosed Phase 1 clinical trial results for DA-1726, a dual GLP-1/glucagon receptor drug candidate, at Europe's major liver disease conference (EASL 2026) in a late-breaking poster—suggesting potentially noteworthy early-stage data.

  Item 7.01 verify on EDGAR →
• low

  The disclosure was furnished under Regulation FD (not formally filed), standard practice for conference presentations and press releases, limiting legal liability while meeting public disclosure requirements.

  Item 7.01 verify on EDGAR →